Protagenic Therapeutics, Inc.\new Q2 2026 Results: Net Loss of $667K, Loss Narrows
Protagenic Therapeutics reported a net loss of $1,630,810 for the six months ended September 30, 2026, compared to a loss of $5,927,010 in the prior year period. The company's cash position significantly decreased from $1,509,178 at March 31, 2026, to $76,909 at September 30, 2026, as it continues to fund research and development and consulting operations.
- Key figure
- Net loss $667K